ABEO
Esto ponía biotech2k en mayo:
ABEO get 4.41 stars
- Management: 4.66 stars
- Clinical Development: 5 stars (1 Breakthrough Therapy)
- Manufacturing: N/A
- Financial Management: 4 stars (Not profitable yet)
- Commercial Sales: N/A
- Good Communications: 5 stars
- Science: 5 stars (1 Breakthrough Therapy)
Abeona is a gene therapy company. They have breakthrough therapy for their RDEB program. They have four ongoing programs around MPS III and CLN disease. They are entering phase 3 with their RDEB program. They have a lot of very small ultra rare disease programs.
- Potential: 5 stars (+259% over 8 years = 32% annual)
EB-101 = $100 million
AB0-101 = $150 million
AB0-102 = $150 million
Total Peak Sales = $400 million * 8 P/S = $3.2 billion Market Cap peak
- Financials: 4 stars (Not Profitable Yet)
Cash = $132 million
Cash Burn = $9 million per quarter
3.5 years of cash
- Risks: 3.4 stars
-Diversified Pipeline: 5 stars (Has 6 drugs in pipeline)
-Stage of Development: 3 stars (Phase 3)
-Commercial: N/A
-Secondaries: 4 stars (3.5 years of cash)
-Clinical Failures: 5 stars (No failures yet)
Total Ranking: 4.41 stars